Skip Navigation Archive: U.S. Department of Health and Human Services www.hhs.gov
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

Summaries of Independent Scientist (K) Awards

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Stahl, James

Institution: Massachusetts General Hospital
Grant Title: Organ Replacement Technology Analysis Project
Grant Number:  K08 HS011637
Duration: 4 years (2003-2007)
Total Award: $519,500

Project Description: The purpose of this project was to develop a model of the liver allocation system to evaluate the costs, effectiveness and systemic implications of non-cadaveric organ replacement technologies (ORT). Using a previously developed and verified model of the current liver allocation system, the model was expanded and used to examine the following three aims:

  1. Determine the role and cost-effectiveness of ORT that are functionally equivalent to cadaveric organs.
  2. Determine the role and cost-effectiveness of ORTs that are temporary or not as effective as cadaveri organ.
  3. Examine liver allocation policy with/without ORTs from the perspective of game theory and ethics. 

Career Goals: Dr. Stahl is a physician in the Institute for Technology Assessment at the Massachusetts General Hospital. He received his M.D. from McGill Medical School, Montreal and served both his internship and residency in internal medicine at North Shore University Hospital, Cornell Medical School and Memorial Sloan-Kettering Cancer. He later earned his M.P.H. from the University of Pittsburgh School of Public Health.

Progress to Date: This grant has been completed. Dr. Stahl found organ replacement technologies production volume and durability remain cost-effectiveness in most cases. Regarding gaming and ethics, clinical urgency is only one of the many factors important to the public and the public may invoke different fairness principles depending on the relative clinical status of patients.

K-Generated Publications:

Stahl JE, Kong N, Schecter SM, Schaeffer AJ, Roberts MS, A methodological framework for optimally re-organizing liver transplant regions.  Medical Decision Making 2005. 25:35-46.

Stahl JE, Tramontano AC, Swan JS, Cohen MJ. Balancing urgency, age and quality of life in organ allocation decisions - what would you do? A survey. Journal of Medical Ethics 2008; 34(2):109-15.

Stahl JE, Egan MT, Goldman JM, Tenney D, Wiklund RA, Sandberg WS, Gazelle S, Rattner DW. Introducing new technology into the OR: Measuring the impact on job performance and satisfaction. Surgery 2005. 137(5):518-26.

Stahl JE, Vacanti JP, Gazelle S. Assessing emerging technologies—the cost of organ replacement technologies: volume, durability, cost. International Journal of Technology Assessment in Health Care 2007; 23(3):331-36.

Return to Career Development Award Grants

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care